Key result
In patients with inoperable lung cancer, no significant response or survival differences were observed between Adriamycin dose schedules, and combination therapy did not improve survival.
Why the study?
Does doxorubicin alone or in combination with cyclophosphamide improve survival or response rates compared to cyclophosphamide alone in patients with inoperable lung cancer?
Population
599 patients with inoperable squamous cell, large cell anaplastic, and adenocarcinoma of the lung
Comparison
Doxorubicin 50 or 75 mg/m2 IV every three weeks… vs Cyclophosphamide
Design
RCT, Patients were randomized to initial therapy... Upon disease progression…
Authors
Loading...
No survival benefit from Adriamycin schedules or cyclophosphamide combination in inoperable lung cancer; confirms limited efficacy and directs research to alternative agents.
RCT (n=599)
Randomized
Does doxorubicin alone or in combination with cyclophosphamide improve survival or response rates compared to cyclophosphamide alone in patients with inoperable lung cancer?
Doxorubicin and cyclophosphamide showed some histology-specific differences in survival and response in inoperable lung cancer, but combination therapy did not increase overall survival.
Hoeltgen et al. (1983) conducted an RCT in Inoperable squamous cell, large cell anaplastic, and adenocarcinoma of the lung (n=599). Adriamycin (doxorubicin) vs. Cytoxan (cyclophosphamide) alone or combined regimen was evaluated on Response and survival. In patients with inoperable lung cancer, no significant response or survival differences were observed between Adriamycin dose schedules, and combination therapy did not improve survival.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: